Report Description
Pancreatic Cancer Treatment Market Outlook 2031:
The global pancreatic cancer treatment market size was valued at USD 2.49 Billion in 2022 and is projected to reach USD 9.25 Billion by 2031, expanding at a CAGR of 15.7% during the forecast period 2023 - 2031, attributed to increasing and wide prevalence of consumption of alcohol, obesity, and smoking. Moreover, if an individual in the family history was somehow predisposed to pancreatitis disease, it is likely that children of the individual may develop pancreatic cancer.
When the cells in the pancreas are growing uncontrollably, it leads to pancreatic cancer. The type of cancer is determined by the cells that get affected by cancer and is categorized as endocrine and exocrine. Pancreatic enzymes in the pancreas are created by exocrine and when these cells are affected by cancer, exocrine pancreatic cancer takes place.
Hormones such as glucagon and insulin are created by endocrine cells, and the presence of cancer cells in these is called endocrine pancreatic cancer. For the diagnosis of this disease, image techniques are used including ultrasound, MRI, and CT scan. The most common therapy provided by oncologists and medical practitioners for treatment is chemotherapy.
At present, the only drugs approved by the U.S Food and Drugs Administration for the treatment of pancreatic cancer treatment are ONIVYDE, ABRAXANE, 5-FU, and Gemzar. Moreover, approval has been granted to a combination of chemotherapies and agents for the treatment of advanced pancreatic cancer and some treatment drugs are under clinical trials.
The COVID-19 pandemic had negative impact on the pancreatic cancer treatment market due to reduced access to hospitals and healthcare services in order to maintain social distancing as per the norms of COVID-19. Not only the pandemic affected the global economy but also disturbs the normal functioning of hospital care.
The pandemic globally impacted the endoscopy units and several studies showed that a decline in endoscopy was observed during this time. The number of surgeries for pancreatic cancer are also substantially reduced due to the pandemic.
Pancreatic Cancer Treatment Market Trends, Drivers, Restraints, and Opportunities
- Rising incidence and wide prevalence of pancreatic cancer among the geriatric population base is expected to propel the growth of the market in the coming years.
- Advancement in molecular biology, diagnostic technology, and the development of drugs are some of key factors anticipated to fuel the market growth during the forecast period.
- Rising initiatives for research & development, the launch of novel products, and scenarios for favorable reimbursement policies are another factors driving the market growth.
- Diagnostics and treatment of pancreatic cancer are high in cost and regulatory guidelines are strict, which act as major restraining factors. These factors are expected to hamper the market growth during the forecast period.
- In order to improve patient-centered care, a huge amount of funds is continuously invested by the governments in developing countries. This is projected to create lucrative opportunities for the market growth.
Scope of Pancreatic Cancer Treatment Market Report
The report on the global pancreatic cancer treatment market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Pancreatic Cancer Treatment Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Affected Regions (Endocrine and Exocrine), Types (Targeted Therapy, Chemotherapy, and Others [Radiation Techniques, Surgery, and Other Therapies])
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Pfizer, Inc.; Clovis Oncology; Celgene Corp.; Amgen, Inc.; Novartis AG; PharmaCyte Biotech; F. Hoffmann-La Roche AG; IncTeva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Eli Lilly and Co.
|
Pancreatic Cancer Treatment Market Segment Insights
Exocrine segment is anticipated to dominate the market
On the basis of affected regions, the global pancreatic cancer treatment market is bifurcated into endocrine and exocrine.
The exocrine segment is expected to dominate the market share in the coming years owing to the increasing reach of novel techniques and rising prevalence.
The endocrine segment, meanwhile, is projected to exhibit a moderate growth rate during the projected period owing to less number of endocrine pancreatic cancer cases as compared to the exocrine segment. However, investments made for research & development are equal in both segments.
Targeted therapy segment is estimated to account for a key market share
Based on types, the market is categorized as targeted therapy, chemotherapy, and others.
The others segment is further divided into radiation techniques, surgery, and other therapies. The targeted therapy segment is estimated to account for a key market share during the forecast period attributed to the commencement of targeted drugs and novel biologic therapies.
Asia Pacific is expect to grow at a rapid pace
In terms of regions, the global pancreatic cancer treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
North America held a high revenue share of the market in 2019 and is anticipated to register a considerable CAGR during the forecast period. The regional market growth is attributed to the existence of the targeted population, rising adoption of procedures for pancreatic treatment, and increasing improvement of healthcare infrastructure in the region.
However, the market of Asia Pacific is expected to grow at a rapid pace attributed to the high presence of the population suffering from pancreatic cancer, critical care centers, and the presence of hospitals in the region.
Segments
The global pancreatic cancer treatment market has been segmented on the basis of
Affected Regions
Types
- Targeted Therapy
- Chemotherapy
- Others
- Radiation Techniques
- Surgery
- Other Therapies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer, Inc.
- Clovis Oncology
- Celgene Corp.
- Amgen, Inc.
- Novartis AG
- PharmaCyte Biotech
- F. Hoffmann-La Roche AG
- IncTeva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Eli Lilly and Co.
Competitive Landscape
Key players competing in the global pancreatic cancer treatment market are Pfizer, Inc.; Clovis Oncology; Celgene Corp.; Amgen, Inc.; Novartis AG; PharmaCyte Biotech; F. Hoffmann-La Roche AG; IncTeva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Eli Lilly and Co.
Many of these players have adopted business strategies such as the launch of new products, advancement of technology, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.
Table Of Content
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pancreatic Cancer Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pancreatic Cancer Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pancreatic Cancer Treatment Market - Supply Chain
4.5. Global Pancreatic Cancer Treatment Market Forecast
4.5.1. Pancreatic Cancer Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pancreatic Cancer Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Pancreatic Cancer Treatment Market Absolute $ Opportunity
5. Global Pancreatic Cancer Treatment Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Pancreatic Cancer Treatment Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
6. North America Pancreatic Cancer Treatment Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Pancreatic Cancer Treatment Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
7. Latin America Pancreatic Cancer Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Pancreatic Cancer Treatment Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
8. Europe Pancreatic Cancer Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Pancreatic Cancer Treatment Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Pancreatic Cancer Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Pancreatic Cancer Treatment Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Pancreatic Cancer Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Pancreatic Cancer Treatment Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Pancreatic Cancer Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Pancreatic Cancer Treatment Market: Market Share Analysis
11.2. Pancreatic Cancer Treatment Distributors and Customers
11.3. Pancreatic Cancer Treatment Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Pfizer, Inc.
11.4.2.
Clovis Oncology
11.4.3.
Celgene Corp.
11.4.4.
Amgen, Inc.
11.4.5.
Novartis AG
11.4.6.
PharmaCyte Biotech
11.4.7.
F. Hoffmann-La Roche AG
11.4.8.
IncTeva Pharmaceutical I